Literature DB >> 12078484

Proteolysis and antigen presentation by MHC class II molecules.

Paula Wolf Bryant1, Ana-Maria Lennon-Duménil, Edda Fiebiger, Cécile Lagaudrière-Gesbert, Hidde L Ploegh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12078484      PMCID： PMC7130937          DOI： 10.1016/s0065-2776(02)80013-x

Source DB:  PubMed          Journal:  Adv Immunol        ISSN： 0065-2776            Impact factor:   3.543


× No keyword cloud information.
  212 in total

Review 1.  Proteases involved in MHC class II antigen presentation.

Authors:  J A Villadangos; R A Bryant; J Deussing; C Driessen; A M Lennon-Duménil; R J Riese; W Roth; P Saftig; G P Shi; H A Chapman; C Peters; H L Ploegh
Journal:  Immunol Rev       Date:  1999-12       Impact factor: 12.988

2.  A role for peptide in determining MHC class II structure.

Authors:  S Sadegh-Nasseri; R N Germain
Journal:  Nature       Date:  1991-09-12       Impact factor: 49.962

3.  Exon 6 is essential for invariant chain trimerization and induction of large endosomal structures.

Authors:  M Gedde-Dahl; I Freisewinkel; M Staschewski; K Schenck; N Koch; O Bakke
Journal:  J Biol Chem       Date:  1997-03-28       Impact factor: 5.157

4.  The proregion of cathepsin L is required for proper folding, stability, and ER exit.

Authors:  K Tao; N A Stearns; J Dong; Q L Wu; G G Sahagian
Journal:  Arch Biochem Biophys       Date:  1994-05-15       Impact factor: 4.013

5.  Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading.

Authors:  R J Riese; P R Wolf; D Brömme; L R Natkin; J A Villadangos; H L Ploegh; H A Chapman
Journal:  Immunity       Date:  1996-04       Impact factor: 31.745

6.  Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization.

Authors:  P A Roche; C L Teletski; E Stang; O Bakke; E O Long
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

7.  The specificity of bovine spleen cathepsin S. A comparison with rat liver cathepsins L and B.

Authors:  D Brömme; A Steinert; S Friebe; S Fittkau; B Wiederanders; H Kirschke
Journal:  Biochem J       Date:  1989-12-01       Impact factor: 3.857

8.  An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation.

Authors:  B Manoury; E W Hewitt; N Morrice; P M Dando; A J Barrett; C Watts
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

9.  Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease.

Authors:  G P Shi; J S Munger; J P Meara; D H Rich; H A Chapman
Journal:  J Biol Chem       Date:  1992-04-15       Impact factor: 5.157

10.  The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity.

Authors:  D Musil; D Zucic; D Turk; R A Engh; I Mayr; R Huber; T Popovic; V Turk; T Towatari; N Katunuma
Journal:  EMBO J       Date:  1991-09       Impact factor: 11.598
View more
  16 in total

Review 1.  In vivo immunogenetics: from MIC to RAET1 loci.

Authors:  Mirjana Radosavljevic; Seiamak Bahram
Journal:  Immunogenetics       Date:  2003-03-20       Impact factor: 2.846

2.  Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells.

Authors:  Azizul Haque; Laela M Hajiaghamohseni; Ping Li; Katherine Toomy; Janice S Blum
Journal:  Cell Immunol       Date:  2007-12-11       Impact factor: 4.868

3.  Cathepsin L is essential for onset of autoimmune diabetes in NOD mice.

Authors:  René Maehr; Justine D Mintern; Ann E Herman; Ana-Maria Lennon-Duménil; Diane Mathis; Christophe Benoist; Hidde L Ploegh
Journal:  J Clin Invest       Date:  2005-09-22       Impact factor: 14.808

4.  Beneficial effects of cathepsin inhibition to prevent chemotherapy-induced intestinal mucositis.

Authors:  I Alamir; N Boukhettala; M Aziz; D Breuillé; P Déchelotte; M Coëffier
Journal:  Clin Exp Immunol       Date:  2010-08-20       Impact factor: 4.330

5.  Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo.

Authors:  K Menzel; M Hausmann; F Obermeier; K Schreiter; N Dunger; F Bataille; W Falk; J Scholmerich; H Herfarth; G Rogler
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

Review 6.  Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.

Authors:  Audry Fernández; Liliana Oliver; Rydell Alvarez; Luis E Fernández; Kelvin P Lee; Circe Mesa
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  Phagosome maturation: going through the acid test.

Authors:  Jason M Kinchen; Kodi S Ravichandran
Journal:  Nat Rev Mol Cell Biol       Date:  2008-10       Impact factor: 94.444

8.  Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.

Authors:  Oliver G Goldstein; Laela M Hajiaghamohseni; Shereen Amria; Kumaran Sundaram; Sakamuri V Reddy; Azizul Haque
Journal:  Cancer Immunol Immunother       Date:  2008-03-15       Impact factor: 6.968

9.  HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor Immunotherapy.

Authors:  Bently Patrick Doonan; Azizul Haque
Journal:  Open Cancer Immunol J       Date:  2010-01-01

10.  Proximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopes.

Authors:  Hualin Li; Chong-Feng Xu; Steven Blais; Qi Wan; Hui-Tang Zhang; Samuel J Landry; Catarina E Hioe
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.